Last 785,000 KRW
Change Today -3,000.00 / -0.38%
Volume 6.6K
001800 On Other Exchanges
Symbol
Exchange
Korea SE
As of 12:59 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

orion corp (001800) Snapshot

Open
783,000
Previous Close
788,000
Day High
786,000
Day Low
781,000
52 Week High
04/24/13 - 1,188,000
52 Week Low
04/16/14 - 763,000
Market Cap
4.7T
Average Volume 10 Days
15.9K
EPS TTM
27,699
Shares Outstanding
6.0M
EX-Date
12/27/13
P/E TM
28.3x
Dividend
3,000
Dividend Yield
0.38%
Current Stock Chart for ORION CORP (001800)

Related News

No related news articles were found.

orion corp (001800) Related Businessweek News

No Related Businessweek News Found

orion corp (001800) Details

Orion Corporation engages in confectionery, entertainment, and sports businesses in South Korea and internationally. It produces and sells confectionery products, including pies, choco pie, chocolates, biscuits, gums, candies and jellies, snacks, and cookies primarily under the Orion Choco Pie, Goraebab, Cuttlefish Peanut Ball, Gosomi, and Choco Chip Cookie, and Choco Cluster brand names; whole wheat cake, crackers, rice chips, shrimp rice chips, and biscuits under the Dr.You brand name; and water cracker, bread chips, brownie, and baked potato fromage under the Market O brand name. The company also engages in the production, investment, and distribution of films; operates theaters under the MEGABOX brand name; and uses public funds raised through the Korean lottery in support of sports development under the Sports TOTO brand. In addition, it operates Orions, a basketball team; presents a range of cultural events, such as magic shows, quick-as-a-flash face mask changing, electronic string music, traditional Korean music, and sports dance; and operates the ‘Little Orions’, a youth basketball club, and a ‘Free Reserved Tickets for Children’ program that provides no-cost tickets to its home games to children who make a reservation in advance. The company was formerly known as Tong Yang Confectionery Corporation and changed its name to Orion Corporation in August 2003. Orion Corporation was founded in 1956 and is headquartered in Seoul, South Korea.

Founded in 1956

orion corp (001800) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

orion corp (001800) Key Developments

Orion Corporation, Annual General Meeting, Mar 28, 2014

Orion Corporation, Annual General Meeting, Mar 28, 2014., at 09:00 Korea Standard Time. Location: Seoul baekbeom Co. headquarters auditorium. Agenda: To approve financial statements for the year ended December 31, 2013; to consider the election of directors; to consider the directors' remuneration limit; and to approval audit fees limit; to approve officers of the regulatory changes in severance payments; and to approve other references useful for making investment decisions.

Orion Corporation Presents at 2014 London Healthcare Conference, Mar-04-2014

Orion Corporation Presents at 2014 London Healthcare Conference, Mar-04-2014 . Venue: Credit Suisse, 20 Columbus Courtyard, Canary Wharf, London E14 4DA, United Kingdom. Speakers: Jari Karlson, CFO, Tukka Hirvonen.

Orion Corporation Signs License Agreement with Janssen Pharmaceuticals, Inc. for the Development and Commercialization of its Novel Treatment for Alzheimer's Disease

Orion Corporation announced that it has entered into a license agreement with Janssen Pharmaceuticals Inc. for the development and commercialization of Orion's novel, investigational alpha-2c adrenoceptor antagonists for the symptoms of Alzheimer's disease, including a clinical phase compound ORM-12741. According to the agreement, Orion will receive an upfront payment of USD 31 million and is eligible to receive milestone payments from Janssen upon successful completion of certain development and commercialization events, as well as royalties on future sales. Orion will use the majority of the up-front payment over the next few years against the costs of the additional Phase IIa study sponsored by Orion. Under the terms of the agreement, Orion will have exclusive commercialization rights in Europe and will grant Janssen a worldwide exclusive license to develop ORM-12741 and other compounds of alpha-2c platform. Janssen will have an exclusive right to commercialize these compounds outside Europe. Orion and Janssen will co-fund the development after an additional Phase IIa study is completed successfully by Orion. The agreement causes no change on Orion's full-year 2013 outlook.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
001800:KS 785,000.00 KRW -3,000.00

001800 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Calbee Inc ¥2,508 JPY +8.00
PepsiCo Inc $85.41 USD +0.27
Want Want China Holdings Ltd $12.36 HKD -0.10
View Industry Companies
 

Industry Analysis

001800

Industry Average

Valuation 001800 Industry Range
Price/Earnings 29.1x
Price/Sales 1.7x
Price/Book 3.8x
Price/Cash Flow 29.8x
TEV/Sales 1.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORION CORP, please visit www.orionworld.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.